Viatris Inc.
VTRS
주식 순위
#1103
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its... Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
주가
$18.25
마지막 동기화: 2026-10-19
시가총액
$20.96B
변동 (1일)
-2.20%
변동 (1년)
76.96%
국가
US
거래 Viatris Inc. (VTRS)
카테고리
Healthcare
Viatris Inc. (VTRS)의 수익
Jun 2026 기준 수익 TTM: $-662.20M
Viatris Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익은 $-662.20M입니다. 2023년에 회사는 $202.90M의 수익을 올렸으며 이는 2022년의 수익 $2.81B과 감소입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Viatris Inc.의 수익 기록 (2004 ~ 2026)
연말 수익
| 연도 | 수익 | 변화 |
|---|---|---|
| 2026 (TTM) | $-662.20M | 6.26% |
| 2024 | $-623.20M | -407.15% |
| 2023 | $202.90M | -92.79% |
| 2022 | $2.81B | -523.42% |
| 2021 | $-664.40M | -7.88% |
| 2020 | $-721.20M | -567.10% |
| 2019 | $154.40M | -48.26% |
| 2018 | $298.40M | -66.95% |
| 2017 | $903.00M | 641.99% |
| 2016 | $121.70M | -86.71% |
| 2015 | $915.40M | -6.06% |
| 2014 | $974.50M | 30.40% |
| 2013 | $747.30M | -7.06% |
| 2012 | $804.08M | 22.83% |
| 2011 | $654.64M | 83.92% |
| 2010 | $355.94M | 56.82% |
| 2009 | $226.98M | -417.19% |
| 2008 | $-71.56M | -95.04% |
| 2007 | $-1.44B | -624.90% |
| 2006 | $274.61M | -12.06% |
| 2005 | $312.25M | -39.09% |
| 2004 | $512.61M | 0.00% |
유사 기업 또는 경쟁사의 수익
| 회사 | 수익 | 수익 차이 | 국가 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | -366.47% |
IN
|
